Medinet: Financial results briefing materials for the fiscal year ending 2024/9
Medinet: Convocation materials for the 29th Annual General Meeting of Shareholders for the fiscal year ending 2024/9 (matters not described in issuance documents)
Medinet: Notice of Convocation of the 29th Annual General Meeting of Shareholders for the fiscal year ending 2024/9
Medinet: Notice Concerning Election of Director Candidates and Audit & Supervisory Board Candidates
Medinet: Notice Concerning Decrease in Capital and Capital Reserve Amounts and Disposal of Surplus Funds
Medinet: Notice regarding the recording of non-operating income and extraordinary losses
Medinet: Summary of Financial Results 2024
Medinet: Summary of financial results for the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
Medinet: Explanatory materials on business plans and growth potential
Medinet: (Changes in disclosure matters) Changes in the use of funds and planned expenditure periods relating to the issuance of stock acquisition rights through third-party allotment
Medinet: [Progress of disclosure matters] Decision to discontinue development of regenerative medicine products for the purpose of treating chronic heart failure
Medinet: (Changes in disclosure matters) Changes in the planned expenditure period relating to the issuance of stock acquisition rights through third-party allotment
Medinet: Notice regarding mass exercise and completion of exercise of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
Medinet: Strategic partnership agreement signed with AGC for cell therapy CDMO business
Medinet: Notice regarding the monthly exercise status of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third-party allotment
Medinet: Announcements of individual stocks regarding the recognition of non-operating revenue.
Medinet: Overview of Q3 2024 financial results.
Medinet: Third quarter financial report for the September 2024 period (Japanese standard) (non-consolidated)
Medinet: Started manufacturing outsourcing for a new specified cell processed product ("S-DSC") related to hair regeneration.
Medinet: (Progress of disclosure matters) Taiwanese regulatory authorities have approved the provision of γδT cell therapy at new medical institutions (progress of licensing agreement with Medigen Biotechnology Corp.)
No Data
No Data